FEMY Femasys Corp: ערך חשבונאי למניה

Femasys Inc. is scaling the FemaSeed system and developing the FemBloc drug, relying on contract component assembly and external logistics. Patent protection for its instruments ensures premium pricing. The book value per share ratio on the GURU.Markets chart confirms this data, where 1.32 reflects the latest metric value, helping investors assess the company's real net asset value.

High marketing expenditures by Femasys Inc. (FEMY) for FemTech solutions and regulatory barriers directly impact the volume of equity. This metric quantifies the share of net assets available to the owner of each share, allowing for an assessment of the real value of assets minus liabilities. By analyzing the book value per share, an investor determines business stability, taking into account the risk of capitalization stagnation despite an increase in the book value.